A5063053665- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urologic and reproductive health conditions
- Statistical Methods in Clinical Trials
- Testicular diseases and treatments
- Glycosylation and Glycoproteins Research
- Virus-based gene therapy research
- Urological Disorders and Treatments
- Renal cell carcinoma treatment
- Cancer Research and Treatments
- Bone health and treatments
- Advanced Radiotherapy Techniques
- Urinary and Genital Oncology Studies
- Global Cancer Incidence and Screening
- Sarcoma Diagnosis and Treatment
- Vascular anomalies and interventions
- Health Sciences Research and Education
- Nutritional Studies and Diet
- Primary Care and Health Outcomes
- HER2/EGFR in Cancer Research
- Health Systems, Economic Evaluations, Quality of Life
- Ureteral procedures and complications
- Digital Radiography and Breast Imaging
- Neurofibromatosis and Schwannoma Cases
McMaster University
2024
Queen Elizabeth Hospital Birmingham
2002-2023
Addenbrooke's Hospital
2023
University Hospitals Birmingham NHS Foundation Trust
2009-2020
Bupa Cromwell Hospital
2019
NIHR Surgical Reconstruction and Microbiology Research Centre
2017-2018
Craigavon Area Hospital
2018
Ulster Hospital
2017
Queen Elizabeth Hospital
2009-2016
University of Bristol
2016
The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain.
Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radiotherapy with hormones outcomes.
Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed 2664 men. Of these men, 1643 were enrolled trial to evaluate effectiveness treatments, with 545 randomly assigned receive active monitoring, 553 undergo prostatectomy, radiotherapy.
The purpose of this study was to evaluate the accuracy Glu-NH-CO-NH-Lys-(Ahx)-[<sup>68</sup>Ga(HBED-CC)] PET compared with morphologic imaging for assessment lymph node metastases (LNM) in patients recurrent prostate cancer. <b>Methods:</b> Forty-eight (median age, 71 y; interquartile range, 66–74 y) biochemical recurrence prostate-specific antigen level, 1.31 ng/mL; 0.75–2.55 ng/mL) who underwent <sup>68</sup>Ga–prostate-specific membrane (PSMA) HBED-CC PET/CT or PET/MR and salvage...
BackgroundLong-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer.MethodsPatient-reported of 1643 randomly assigned participants in the ProtecT (Prostate Testing Cancer and Treatment) trial were evaluated assess functional quality-of-life impacts prostatectomy, radiotherapy with neoadjuvant androgen deprivation, active monitoring. This article focuses on from 7 12 years using mixed effects linear logistic models.ResultsResponse rates...
The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. To determine report outcomes according treatment received in randomised choice cohorts. This study focuses on secondary care. Men clinically at one nine UK centres were invited participate the comparing AM, Two cohorts included 1643 who agreed be randomised; 997 declined randomisation chose...
To investigate the functional and quality of life (QoL) outcomes treatments for localised prostate cancer inform treatment decision-making.Men aged 50-69 years diagnosed with by prostate-specific antigen testing biopsies at nine UK centres in Prostate Testing Cancer Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) concurrent...
We report a phase I/II clinical trial in prostate cancer (PCa) using direct intraprostatic injection of replication defective adenovirus vector (CTL102) encoding bacterial nitroreductase (NTR) conjunction with systemic prodrug CB1954. One group patients localized PCa scheduled for radical prostatectomy received virus alone, prior to surgery, dose escalation establish safety, tolerability, and NTR expression. A second local failure following primary treatment plus safety tolerability. Based...
Background Prostate cancer is the most common among men in UK. Prostate-specific antigen testing followed by biopsy leads to overdetection, overtreatment as well undertreatment of disease. Evidence treatment effectiveness has lacked because paucity randomised controlled trials comparing conventional treatments. Objectives To evaluate treatments for localised prostate (active monitoring, radical prostatectomy and radiotherapy) aged 50–69 years. Design A prospective, multicentre...
Early detection and treatment of asymptomatic men with advanced high-risk prostate cancer (PCa) may improve survival rates. To determine outcomes for diagnosed PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial. Mortality was compared 492 followed up a median 7.4 yr to contemporaneous cohort UK Anglia Cancer Network (ACN) matched subset ACN. PCa-specific all-cause mortality using Kaplan-Meier analysis Cox's proportional hazards...
Increasingly invasive bladder cancer cells lines displayed insensitivity toward a panel of dietary-derived ligands for members the nuclear receptor superfamily. Insensitivity was defined through altered gene regulatory actions and cell proliferation reflected both reduced expression elevated corepressor 1 (NCOR1) expression. Stable overexpression NCOR1 in sensitive (RT4) resulted clones that recapitulated resistant phenotype terms proliferative responses ligand. Similarly, silencing RNA...
Radical retropubic prostatectomy is considered by many centres to be the treatment of choice for men aged less than 70 years with localized prostate cancer. A rise in serum prostate-specific antigen after radical occurs 10–40% cases. This study evaluates usefulness novel ultrasensitive PSA assays early detection biochemical relapse. 200 patients mean age 61.2 underwent prostatectomy. Levels ≤ 0.01 ng ml–1 were undetectable. Mean pre-operative was 13.3 ml–1. Biochemical relapse defined as 3...
Surgery is the most effective treatment for management of patients with renal cell carcinoma (RCC) and involvement inferior vena cava (IVC). Data were accrued 68 consecutive patients, who underwent surgical resection RCC IVC extension required cardiothoracic input from May 1993 to 2005. The mean age was 60.7 years (range 25-84, S.D. 11.6 years), 49 these males. majority application vascular clamp at junction right atrium (RA), however, 21 cardiopulmonary bypass (CPB) (29-193 min, 131 min)....
Background: Parental height data are essential in the assessment of linear growth children. A number studies have documented inaccuracy self-reported adult height. Aims: To determine whether there is a tendency for men to overestimate and women underestimate their Methods: Heights parents children attending outpatient clinics were measured (MHt) compared with reported heights (RHt). Results: Two hundred (100 males; 100 females), mean (range) age 37.8 (20.8–69.3) years, measured. Males...
There is limited evidence relating to the cost-effectiveness of treatments for localised prostate cancer.
Objectives Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols determine leaves uncertainties for and clinicians. This study investigated men’s strategies coping the active monitoring (AM, a strategy within Prostate testing Treatment, ProtecT trial) over longer term implications optimising supportive care. Design Longitudinal serial in-depth qualitative interviews every 2–3...
Abstract Background Optimal management strategies for clinically localised prostate cancer are debated. Using median 10-year data from the largest randomised controlled trial to date (ProtecT), lifetime cost-effectiveness of three major treatments (radical radiotherapy, radical prostatectomy and active monitoring) was explored according age risk subgroups. Methods A decision-analytic (Markov) model developed informed by clinical input. The economic evaluation adopted a UK NHS perspective...
The characteristic sclerotic appearance of bone metastases from prostate cancer is unexplained but could involve excess peritumoural activity osteoblast mitogens such as the insulin-like growth factors (IGFs). Since prostatic are distinguished by androgen-dependent secretion prostate-specific antigen (PSA), a serine protease which cleaves extracellular IGF-binding proteins and thereby enhances bioavailability IGFs, relationship was examined between tumour PSA expression osteoblastic...